DOCSLIB.ORG

Case Report Granulocyte Transfusion As a Treatment for Enterococcal Meningoencephalitis After Allogeneic Bone Marrow Transplantation from an Unrelated Donor

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Case Report Granulocyte Transfusion As a Treatment for Enterococcal Meningoencephalitis After Allogeneic Bone Marrow Transplantation from an Unrelated Donor Bone Marrow Transplantation (2003) 31, 69–72 & 2003 Nature Publishing Group All rights reserved 0268-3369/03 $25.00 www.nature.com/bmt Case report Granulocyte transfusion as a treatment for enterococcal meningoencephalitis after allogeneic bone marrow transplantation from an unrelated donor Y Tsukada1, H Nagayama1, T Mori1, T Shimizu1, N Sato1, N Takayama1, A Ishida2, M Handa2, Y Ikeda1 and S Okamoto1 1Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; and 2Blood Center, Keio University School of Medicine, Tokyo, Japan Summary: serious problem during the pre-engraftment period follow- ing BMT.1–3 However, Enterococci rarely cause CNS Bacterial meningoencephalitis occurring in the pre-en- infection in granulocytopenic patients, and there are few graftment period after bone marrow transplantation anecdotal cases of meningoencephalitis due to Enterococcus (BMT) is a rare complication, and the feasibility of faecalis after BMT.4–6 Transfusion of normal granulocytes granulocyte transfusion (GTX) in such cases remains to be is a logical treatment for severe bacterial infections in elucidated. A 37-year-old man developed enterococcal neutropenic patients. However, granulocyte transfusion meningoencephalitis during a severely granulocytopenic (GTX)had a limited role in the treatment of such infections pre-engraftment period after BMT. Despite therapy with before the wide clinical use of granulocytes colony appropriate antibiotics, cultures of blood and cerebro- stimulating factor (G-CSF). A major reason for the lack spinal fluid (CSF) continued to grow Enterococcus of efficacy was that the dose of granulocytes collected and faecalis, and he developed rapid mental deterioration transfused was inadequate. The availability of G-CSF and seizure. Granulocytes were collected from his HLA- prompted several investigators to re-evaluate the efficacy mismatched, ABO-matched sibling with subcutaneous of GTX in the treatment of uncontrolled bacterial and injection of granulocyte colony-stimulating factor (G- fungal infection during granulocytopenia. Bielorai et al CSF) and oral dexamethazone. Transfusion of 4.4 Â 1010 reported a case of VRE septicemia in a neutropenic patient, granulocytes resulted in a 12-h post-transfusion granulo- which was successfully treated with GTX.3 The phase I/II cyte increment of 2.0 Â 109/l, and maintained peripheral trials of GTX mobilized by G-CSF for the treatment of blood granulocyte counts above 0.5 Â 109/l for 3 days. A infections complicated with hematological disorders also rapid increase of granulocytes in CSF was also observed, demonstrated its efficacy.7 These trials also demonstrated and cultures of blood and CSF became negative after the migratory activity of transfused granulocytes to the GTX. A transient worsening of seizure was observed as a tissue site; however, whether transfused granulocytes potential side effect of GTX. The patient subsequently migrate to the central nervous system (CNS)remains developed septic shock because of Pseudomonas aerugi- unknown. nosa and died. Further studies are warranted to evaluate In this report, we describe a case of enterococcal the clinical efficacy of GTXfor the treatment of meningoencephalitis before marrow engraftment, and uncontrolled infections in granulocytopenic stem cell discuss the feasibility and efficacy of GTX against CNS transplant recipients. infection. Bone MarrowTransplantation (2003) 31, 69–72. doi:10.1038/sj.bmt.1703780 Case report Keywords: enterococcus; meningoencephalitis; granulo- cyte transfusion; G-CSF; bone marrow transplantation A 37-year-old man was diagnosed with acute myeloblastic leukemia with tri-lineage dysplasia (tMDS-AML)in August 2000. Complete remission was achieved with Bacterial or fungal infections continue to be a major cause combination chemotherapy consisting of idarubicin (IDR) of morbidity and mortality during the post-transplant and cytosine arabinoside (CA). One additional course of period until engraftment. Recently, the incidence of the same chemotherapy was given and the patient was vancomycin-resistant Enterococcus (VRE)-related infec- followed as an outpatient without further chemotherapy. tion has been increasing, and its treatment has become a He was admitted to the Keio University Hospital in September 2001 to undergo allogeneic bone marrow Correspondence: Dr Nagayama, Division of Hematology, Department of Medicine, Keio University School of Medicine, 35, Shinanomachi, transplantation (BMT)from an HLA-matched unrelated Shinjyuku-ku, Tokyo 160-8582, Japan donor. Although the patient had remained in complete Received 15 April 2002; accepted 30 July 2002 remission, bone marrow examination 3 weeks before the GTX for meningoencephalitis after BMT Y Tsukada et al 70 transplant showed 21.6% blastic cells, indicating that he Table 1 Findings of cerebrospinal fluid before and after granulo- was in first relapse. A lumbar puncture on day À12 did not cyte transfusion show leukemic cells in the cerebrospinal fluid (CSF), and a Before GTX After GTX combination of methotrexate (MTX), CA, and hydrocorti- (Day +13) (Day +17) sone sodium succinate was given intrathecally for the Total cell count (mm3)27 966 prophylaxis of CNS leukemia. Culture of CSF was not Monocytes (mm3)25 139 performed. A pretransplantation evaluation that included Neutrophils (mm3)2 827 whole body computed tomography (CT), radioisotope Total protein (mg/dl)333 72 imaging, and ophthalmologic, oto-rhino-pharyngeal, den- LDH (IC/l)88 83 tal, and perianal examination failed to detect any infectious Chloride (mEq/l)114 114 Glucose (mg/dl)94 110 foci. Oral ciprofloxacin hydrochloride (CPFX)at a dose of Plasma glucose (mg/dl)145 284 600 mg/day and fluconazole (FCZ)at a dose of 200 mg/day Granulocyte counts (PB)100 2000 were started on day À14 as gut decontamination. The conditioning regimen consisted of total body irradiation (2 Gy twice daily for three consecutive days)followed by CA (3 g/m2 twice daily i.v. for four consecutive days). The WBC count was 2.6 Â 109/L on the day of starting the ml)to CPFX in vitro. Cardiac echography failed to detect conditioning (day À8), and became less than 0.5 Â 109/L on any vegetations in the heart. day À2. Transplantation of 1.8 Â 108/kg of bone marrow Despite therapy with appropriate antibiotics, the infec- mononuclear cells from an HLA-matched unrelated donor tion remained uncontrolled, and GTX was performed using was then performed, and intravenous G-CSF at a dose of an HLA-mismatched ABO-compatible elder brother as 5 mg/kg/day was started from day +1. Cyclosporine (CyA) donor. After providing his informed, written consent, the and short-term MTX were administered for GVHD donor received dexamethasone 8 mg orally and G-CSF prophylaxis. Acyclovir (ACV)was administered intrave- 10 mg/kg subcutaneously approximately 12 h before the nously from day À3 to day +14 of BMT as prophylaxis scheduled granulocyte collection. Granulocytes were col- against herpes viruses. Surveillance cultures before trans- lected as per standard leukapheresis, processing 8 l of plantation revealed the presence of methicillin-sensitive blood. No serious adverse events, apart from bone pain, Staphylococcus aureus (MSSA)and a-hemolytic strepto- insomnia, and flushing, were observed in the donor. coccus in the throat, and Staphylococcus epidermidis in the Granulocytes 44 Â 109 were collected and irradiated at nasal cavity. Repeat urine and stool cultures failed to grow 25 Gy, then transfused to the patient on day +13 any bacteria, including Enterococcus faecalis. On day À2, (Figure 1). Peripheral blood granulocyte counts rose to the patient began to complain of lower abdominal 2.0 Â 109/l at 12 h after GTX and remained above 0.5 Â 109/ cramping pain and watery diarrhea. The diarrhea became l for 3 days. Cultures of peripheral blood and CSF more frequent on day +2, and was accompanied by an became negative and serum CRP levels gradually de- elevated serum CRP value (2.07 mg/dl)and low-grade fever creased. Table 1 shows the CSF findings before and after (37.31C). Oral CPFX was discontinued, and intravenous GTX. The absolute granulocyte count in the CSF increased ceftazidime (CAZ)(4 g/day)and arbekacin sulfate (ABK) dramatically after GTX, suggesting migratory activity (150 mg/day once daily)were started. The fever and CRP of transfused granulocytes into the CSF. However, a resolved gradually, but the diarrhea continued. On day +9, transient worsening of the seizures was observed. On day his body temperature rose to 39.61C. Because the throat +16, CFPM was discontinued and intravenous and and stool cultures taken on day +5 grew Enterococcus intrathecal administration of gentamicin sulfate (GM) faecalis, the intravenous antibiotics were changed to was started. Blood cultures grew Pseudomonas aeruginosa meropenem trihydrate (MEPM)(1.5 g/day)and vancomy- on day +20, and the patient went into septic shock. cin hydrochloride (VCM)(1.5 g/day).On day +11, he Repeated GTX was not planned because he developed began to complain of severe headache, then developed a multiorgan failure. He died on day +20 without any grand mal seizure. Results of a CT scan of the brain were evidence of marrow recovery. Permission for an autopsy unremarkable. The patient was placed on phenytoin and was declined by his family. valproate sodium, and intravenous ampicillin sodium (ABPC)(12 g/day),and cefepime dihydrochloride (CFPM) (4 g/day)were started in addition to VCM and ACV. Discussion Mechanical ventilation was required on day +13 to control persistent convulsions. Blood cultures on days +9 and Two important aspects of this case merit attention: the +10 grew Enterococcus faecalis. Lumbar puncture yielded presence of enterococcal meningitis, a rare infectious cloudy CSF with protein 333 mg/dl, glucose 94 mg/dl complication immediately after BMT, and the use of (serum glucose 134 mg/dl), and a cell count of 27/mm3 GTX as part of its treatment.1,2 (with monocytes 25/27, and granulocytes 2/27). The culture Enterococci are unusual etiologic agents of bacterial of CSF also grew Enterococcus faecalis (Table 1).
Load more

Recommended publications
  • Cells, Tissues and Organs of the Immune System
    Immune Cells and Organs Bonnie Hylander, Ph.D. Aug 29, 2014 Dept of Immunology [email protected] Immune system Purpose/function? • First line of defense= epithelial integrity= skin, mucosal surfaces • Defense against pathogens – Inside cells= kill the infected cell (Viruses) – Systemic= kill- Bacteria, Fungi, Parasites • Two phases of response – Handle the acute infection, keep it from spreading – Prevent future infections We didn’t know…. • What triggers innate immunity- • What mediates communication between innate and adaptive immunity- Bruce A. Beutler Jules A. Hoffmann Ralph M. Steinman Jules A. Hoffmann Bruce A. Beutler Ralph M. Steinman 1996 (fruit flies) 1998 (mice) 1973 Discovered receptor proteins that can Discovered dendritic recognize bacteria and other microorganisms cells “the conductors of as they enter the body, and activate the first the immune system”. line of defense in the immune system, known DC’s activate T-cells as innate immunity. The Immune System “Although the lymphoid system consists of various separate tissues and organs, it functions as a single entity. This is mainly because its principal cellular constituents, lymphocytes, are intrinsically mobile and continuously recirculate in large number between the blood and the lymph by way of the secondary lymphoid tissues… where antigens and antigen-presenting cells are selectively localized.” -Masayuki, Nat Rev Immuno. May 2004 Not all who wander are lost….. Tolkien Lord of the Rings …..some are searching Overview of the Immune System Immune System • Cells – Innate response- several cell types – Adaptive (specific) response- lymphocytes • Organs – Primary where lymphocytes develop/mature – Secondary where mature lymphocytes and antigen presenting cells interact to initiate a specific immune response • Circulatory system- blood • Lymphatic system- lymph Cells= Leukocytes= white blood cells Plasma- with anticoagulant Granulocytes Serum- after coagulation 1.
    [Show full text]
  • Granulocyte Transfusions in Haematopoietic Cell Transplants and Leukaemia: the Phoenix Or Beating a Dead Horse?
    www.nature.com/bmt EDITORIAL Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse? © The Author(s), under exclusive licence to Springer Nature Limited 2021 Bone Marrow Transplantation (2021) 56:2046–2049; https://doi.org/10.1038/s41409-021-01399-3 You should make a point of trying every experience once, excepting incest and folk-dancing. (and perhaps granulocyte transfusions?) Sir Arnold Bax Why is it some things which are so intuitive and seem easily proved continue engendering controversy and debate (Fig. 1). The example at hand is granulocyte transfusions. It has been known for >50 years infection risk increases precipitously in people when their blood granulocyte concentration is <0.5 × 10E + 9/L [1, 2] (Fig. 2). Whether, given the development of more effective systemic and oral non-absorbable antibiotics and anti-fungal drugs, often given prophylactically 0.5 × 10E + 9/L remains the threshold for increased infection risk or whether the threshold is closer 0–0.2 × 10E + 9/L is unknown. It is also possible there is no blood granulocyte nadir requiring granulocyte transfusions or where a benefit of granulocyte transfusions can be convincingly proved. Regardless, the seemingly simple remedy to decreased Fig. 1 Centre for the Study of Rationality. Hebrew Univ. Jerusalem. blood granulocytes is to transfuse granulocytes from normals or, formally, from persons with chronic myeloid leukaemia (CML). Amino™ (now renamed CelltrifugeTM)orbyfiltration leukapheresis Why should granulocyte transfusions be different than RBC and in persons with granulocytopenia and gram-negative sepsis. platelet transfusions which are convincingly safe and effective.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • An EANM Procedural Guideline
    European Journal of Nuclear Medicine and Molecular Imaging https://doi.org/10.1007/s00259-018-4052-x GUIDELINES Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline A. Signore1 & F. Jamar2 & O. Israel3 & J. Buscombe4 & J. Martin-Comin5 & E. Lazzeri6 Received: 27 April 2018 /Accepted: 6 May 2018 # The Author(s) 2018 Abstract Introduction Radiolabelled autologous white blood cells (WBC) scintigraphy is being standardized all over the world to ensure high quality, specificity and reproducibility. Similarly, in many European countries radiolabelled anti-granulocyte antibodies (anti-G-mAb) are used instead of WBC with high diagnostic accuracy. The EANM Inflammation & Infection Committee is deeply involved in this process of standardization as a primary goal of the group. Aim The main aim of this guideline is to support and promote good clinical practice despite the complex environment of a national health care system with its ethical, economic and legal aspects that must also be taken into consideration. Method After the standardization of the WBC labelling procedure (already published), a group of experts from the EANM Infection & Inflammation Committee developed and validated these guidelines based on published evidences. Results Here we describe image acquisition protocols, image display procedures and image analyses as well as image interpre- tation criteria for the use of radiolabelled WBC and monoclonal antigranulocyte antibodies. Clinical application for WBC and anti-G-mAb scintigraphy is also described. Conclusions These guidelines should be applied by all nuclear medicine centers in favor of a highly reproducible standardized practice. Keywords Infection .
    [Show full text]
  • Granulocyte Serology: Current Concepts and Clinical Signifcance
    Review Granulocyte serology: current concepts and clinical signifcance M.E. Clay, R.M. Schuller, and G.J. Bachowski Applying serologic procedures to the detection of RBC and lym- Clinical Significance phocyte antigens has facilitated the identification of granulo- Alloimmune Neonatal Neutropenia cyte antigens with established clinical significance, which are Neutropenia observed in the neonate is primarily the now classified in the human neutrophil antigen system. Granu- result of neutrophil-specific alloantibodies transplacentally locyte alloantibodies and autoantibodies have been implicated transferred to the fetus from the maternal circulation. The in a variety of clinical conditions including alloimmune neutro- penia, autoimmune neutropenia, febrile and severe pulmonary presence of these human neutrophil antigen (HNA) anti- transfusion reactions, drug-induced neutropenia, refractori- bodies most likely is the result of prenatal maternal sensi- ness to granulocyte transfusions, and immune neutropenia tization by fetal neutrophils crossing the placental barrier, after hematopoietic stem cell transplantation. Although the although the antibodies may have also arisen in association intrinsically fragile nature of granulocytes contributes to the in- with autoimmune diseases such as systemic lupus herent challenges of granulocyte serology, several advances in erythematosus or rheumatoid arthritis.2,3 Mater- laboratory procedures have improved detection of granulocyte nal alloimmunization can occur anytime after the first antibodies. This
    [Show full text]
  • Neutrophils (A.K.A
    Neutrophils (a.k.a. leukocyte, granulocyte, white blood cell, WBC) blood cells on a microscope slide showing the lobed nucleus of two neutrophils a 3-d drawing of a neutrophil This chart shows how blood cells are produced in the bone marrow from “stem cells” and how we organize them into groups. By Mikael Häggström The Mul(faceted Func(ons of Neutrophils Tanya N. Mayadas,1 Xavier Cullere,1 and Clifford A. Lowell2 “Neutrophils and neutrophil-like cells are the major pathogen-fighKng immune cells in organisms ranging from slime molds to mammals. Central to their funcKon is their ability to be recruited to sites of infecKon, to recognize and phagocytose (eang foreign objects like bacteria) microbes, and then to kill pathogens through a combinaon of cytotoxic mechanisms.” Form • average diameter of 12-15 micrometers (µm) in peripheral blood smears • in suspension, neutrophils have an average diameter of 8.85 µm • mulK-lobed shape nucleus • survive for only 8–12 h in the circulaon and up to 1–2 days in Kssues • Neutrophils will show increasing segmentaon (many segments of nucleus) as they mature. A normal neutrophil should have 3-5 segments. • Neutrophils account for approximately 50-70% of all white blood cells (leukocytes) Func(on • first line of host defense against a wide range of infecKous pathogens including bacteria, fungi, and protozoa • Neutrophils are generated at a rate of 1011 per day, which can increase to 1012 per day during bacterial infection. • Researchers once believed that neutrophils were present only during the most acKve phase of an infecKon, funcKoning as pathogen killers.
    [Show full text]
  • Blood and Immunity
    Chapter Ten BLOOD AND IMMUNITY Chapter Contents 10 Pretest Clinical Aspects of Immunity Blood Chapter Review Immunity Case Studies Word Parts Pertaining to Blood and Immunity Crossword Puzzle Clinical Aspects of Blood Objectives After study of this chapter you should be able to: 1. Describe the composition of the blood plasma. 7. Identify and use roots pertaining to blood 2. Describe and give the functions of the three types of chemistry. blood cells. 8. List and describe the major disorders of the blood. 3. Label pictures of the blood cells. 9. List and describe the major disorders of the 4. Explain the basis of blood types. immune system. 5. Define immunity and list the possible sources of 10. Describe the major tests used to study blood. immunity. 11. Interpret abbreviations used in blood studies. 6. Identify and use roots and suffixes pertaining to the 12. Analyse several case studies involving the blood. blood and immunity. Pretest 1. The scientific name for red blood cells 5. Substances produced by immune cells that is . counteract microorganisms and other foreign 2. The scientific name for white blood cells materials are called . is . 6. A deficiency of hemoglobin results in the disorder 3. Platelets, or thrombocytes, are involved in called . 7. A neoplasm involving overgrowth of white blood 4. The white blood cells active in adaptive immunity cells is called . are the . 225 226 ♦ PART THREE / Body Systems Other 1% Proteins 8% Plasma 55% Water 91% Whole blood Leukocytes and platelets Formed 0.9% elements 45% Erythrocytes 10 99.1% Figure 10-1 Composition of whole blood.
    [Show full text]
  • I M M U N O L O G Y Core Notes
    II MM MM UU NN OO LL OO GG YY CCOORREE NNOOTTEESS MEDICAL IMMUNOLOGY 544 FALL 2011 Dr. George A. Gutman SCHOOL OF MEDICINE UNIVERSITY OF CALIFORNIA, IRVINE (Copyright) 2011 Regents of the University of California TABLE OF CONTENTS CHAPTER 1 INTRODUCTION...................................................................................... 3 CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS ..............................................9 CHAPTER 3 ANTIBODY STRUCTURE I..................................................................17 CHAPTER 4 ANTIBODY STRUCTURE II.................................................................23 CHAPTER 5 COMPLEMENT...................................................................................... 33 CHAPTER 6 ANTIBODY GENETICS, ISOTYPES, ALLOTYPES, IDIOTYPES.....45 CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION..................................................................53 CHAPTER 8 GENETIC BASIS OF ANTIBODY DIVERSITY...................................61 CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS ...............................................69 CHAPTER 10 BLOOD GROUPS: ABO AND Rh .........................................................77 CHAPTER 11 CELL-MEDIATED IMMUNITY AND MHC ........................................83 CHAPTER 12 CELL INTERACTIONS IN CELL MEDIATED IMMUNITY ..............91 CHAPTER 13 T-CELL/B-CELL COOPERATION IN HUMORAL IMMUNITY......105 CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES...............................................................111
    [Show full text]
  • Circular of Information for the Use of Human Blood and Blood Components
    CIRCULAR OF INFORMATION FOR THE USE OF HUMAN BLOOD Y AND BLOOD COMPONENTS This Circular was prepared jointly by AABB, the AmericanP Red Cross, America’s Blood Centers, and the Armed Ser- vices Blood Program. The Food and Drug Administration recognizes this Circular of Information as an acceptable extension of container labels. CO OT N O Federal Law prohibits dispensing the blood and blood compo- nents describedD in this circular without a prescription. THIS DOCUMENT IS POSTED AT THE REQUEST OF FDA TO PROVIDE A PUBLIC RECORD OF THE CONTENT IN THE OCTOBER 2017 CIRCULAR OF INFORMATION. THIS DOCUMENT IS INTENDED AS A REFERENCE AND PROVIDES: Y • GENERAL INFORMATION ON WHOLE BLOOD AND BLOOD COMPONENTS • INSTRUCTIONS FOR USE • SIDE EFFECTS AND HAZARDS P THIS DOCUMENT DOES NOT SERVE AS AN EXTENSION OF LABELING REQUIRED BY FDA REGUALTIONS AT 21 CFR 606.122. REFER TO THE CIRCULAR OF INFORMATIONO WEB- PAGE AND THE DECEMBER 2O17 FDA GUIDANCE FOR IMPORTANT INFORMATION ON THE CIRCULAR. C T O N O D Table of Contents Notice to All Users . 1 General Information for Whole Blood and All Blood Components . 1 Donors . 1 Y Testing of Donor Blood . 2 Blood and Component Labeling . 3 Instructions for Use . 4 Side Effects and Hazards for Whole Blood and P All Blood Components . 5 Immunologic Complications, Immediate. 5 Immunologic Complications, Delayed. 7 Nonimmunologic Complications . 8 Fatal Transfusion Reactions. O. 11 Red Blood Cell Components . 11 Overview . 11 Components Available . 19 Plasma Components . 23 Overview . 23 Fresh Frozen Plasma . .C . 23 Plasma Frozen Within 24 Hours After Phlebotomy . 28 Components Available .
    [Show full text]
  • Ch33 WO Pt1.Pdf
    33 Innate Host Resistance 1 33.1 Innate Resistance Overview 1. Identify the major components of the mammalian host immune system 2. Integrate the major immune components and their functions to explain in general terms how the immune system protects the host 2 Host Resistance Overview • Most pathogens (disease causing microbes) – must overcome surface barriers and reach underlying – overcome resistance by host • nonspecific resistance • specific immune response 3 Host Resistance Overview… • Immune system – composed of widely distributed cells, tissues, and organs – recognizes foreign substances or microbes and acts to neutralize or destroy them • Immunity – ability of host to resist a particular disease or infection • Immunology – science concerned with immune responses 4 Immunity • Nonspecific immune response – Aka nonspecific resistance, innate, or natural immunity – acts as a first line of defense – offers resistance to any microbe or foreign material – lacks immunological memory • Specific immune response – Aka acquired, adaptive, or specific immunity – resistance to a particular foreign agent – has “memory” • effectiveness increases on repeated exposure to agent 5 6 Antigens • Recognized as foreign • Invoke immune responses – presence of antigen in body ultimately results in B cell activation production of antibodies • antibodies bind to specific antigens, inactivating or eliminating them • other immune cells also become activated • Name comes from antibody generators 7 White Blood Cells of Innate and Adaptive Immunity • White blood
    [Show full text]
  • Cells of the Immune System and Innate Immunity
    Harvard-MIT Division of Health Sciences and Technology HST.176: Cellular and Molecular Immunology Course Director: Dr. Shiv Pillai Cells of the Immune System and Innate Immunity Recommended reading: Abbas et al., 4th edition, Chapters 2 and 12 Janeway and Travers, 5th edition, Chapters 1 and 10 The innate immune system is made up of molecules and cellular processes that defend the host within minutes and hours after exposure to a noxious stimulus. It is the only immune system in plants and invertebrates. Innate immune responses may initiate acute inflammation, which basically involves the accumulation and activation of phagocytes (mainly polymorphonuclear cells in man) and of vascular endothelium at sites of injury. In vertebrates, the innate and adaptive immune systems talk to each other and there is an important reciprocal interplay that operates between these systems. In these animals the cells and molecules of the innate immune system provide immediate protection and then set in motion the activation of the adaptive immune response. The adaptive immune response in turn “revs” up innate immune mechanisms of host defense. The innate immune system uses non-clonal “pattern recognition” receptors (PRRs) which cannot recognize host structures but which do recognize patterns found on microbes.These are sometimes called PAMPs for Pathogen Associated Molecular Patterns. Pathogens/ microbes The most common organisms that cause disease are viruses, bacteria, fungi, protozoa, and worms. A microbe (a small invader) or a worm that does not cause disease in most people may generally be classified as non-pathogenic. Such an organism will provoke an immune response in a normal immunocompetent host.
    [Show full text]
  • Granulocyte Colony-Stimulating Factor (G-CSF)
    British Journal of Cancer (1999) 80(1/2), 229–235 © 1999 Cancer Research Campaign Article no. bjoc.1998.0344 Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response E Reyes1, I García-Castro2, F Esquivel1, J Hornedo2, H Cortes-Funes2, J Solovera3 and M Alvarez-Mon1 1Medicine/Immune System Diseases Oncology Service, Department of Medicine ‘Principe de Asturias’ University Hospital, Alcalá University, Carretera Madrid- Barcelona, Km 33.600, 28871 Alcalá de Henares, Madrid, Spain; 2Medical Oncology Department, ‘12 de Octubre’ University Hospital, Madrid, Spain; 3Amgen, S.A. Barcelona, Spain Summary Granulocyte colony-stimulation factor (G-CSF) is a cytokine that selectively promotes growth and maturation of neutrophils and may modulate the cytokine response to inflammatory stimuli. The purpose of this study was to examine the effect of G-CSF on ex vivo peripheral blood mononuclear cell (PBMC) functions. Ten patients with breast cancer were included in a clinical trial in which r-metHuG-CSF was administrered daily for 5 days to mobilize peripheral blood stem cells. Ten healthy women were also included as controls. Our data show that G-CSF treatment induces an increase in peripheral blood leucocyte, neutrophil, lymphocyte and monocyte counts. We have found a modulation in the percentages of CD19+, CD45+CD14+, CD4+CD45RA+ and CD4+CD45RO+ cells in PBMC fractions during G-CSF treatment. We have also found a significant reduction in the proliferative response of PBMC to mitogenic stimulation that reverted 14 days after the fifth and the last dose of G-CSF. Furthermore, it was not associated with significant changes in the pattern of cytokine production.
    [Show full text]